Last reviewed · How we verify
Gastrointestinal stromal tumor
Approved treatments
- Jeselhy · Taiho Pharmaceutical Co., Ltd
- Sutent · Pfizer
Sunitinib is a small-molecule, multi-targeted receptor tyrosine kinase inhibitor that inhibits PDGFRα, PDGFRβ, VEGFR1, VEGFR2, and KIT. - Sunitinib Malate · Pfizer
Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases, including PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, CSF-1R, and RET. - Gleevec · M.D. Anderson Cancer Center
- Sutent · Pfizer
Sunitinib inhibits multiple receptor tyrosine kinases implicated in tumor growth, angiogenesis, and metastatic progression. - Gleevec · Novartis
Gleevec works by blocking the activity of specific enzymes involved in cancer cell growth and proliferation. - Ayvakit · Blueprint Medicines
Ayvakit works by blocking the activity of the PDGFRA protein, which is involved in the growth and spread of cancer cells. - Stivarga · Bayer
Stivarga blocks the activity of enzymes involved in tumor growth and angiogenesis.
Clinical guidelines
- FDA label — 2L
Sunitinib malate is indicated for the treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. - FDA label — 1L
Sunitinib malate is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC). - FDA label — 1L
Sunitinib malate is indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease. - FDA label — 2L
Sunitinib malate is indicated for the treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. - FDA label — 1L
Sunitinib malate is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC). - FDA label — 1L
Sunitinib malate is indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Gastrointestinal stromal tumor patent landscape — cliff calendar, originator estates, attackable patents
- Gastrointestinal stromal tumor treatment landscape brief
- Gastrointestinal stromal tumor treatment updates RSS
Frequently asked questions about Gastrointestinal stromal tumor
What drugs treat Gastrointestinal stromal tumor?
Tracked treatments include Jeselhy, Sutent, Sunitinib Malate, Gleevec, Ayvakit, Stivarga.
What is the treatment for Gastrointestinal stromal tumor?
Standard treatment for Gastrointestinal stromal tumor includes Jeselhy, Sutent, Sunitinib Malate, Gleevec, Ayvakit. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Gastrointestinal stromal tumor?
FDA label publishes guidelines for Gastrointestinal stromal tumor. 6 guideline references tracked.
Related
- Treatment landscape: Gastrointestinal stromal tumor patent cliff · Gastrointestinal stromal tumor CI report
- Treatment: Jeselhy · Taiho Pharmaceutical Co., Ltd
- Treatment: Sutent · Pfizer
- Treatment: Sunitinib Malate · Pfizer
- Treatment: Gleevec · M.D. Anderson Cancer Center
- Treatment: Sutent · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing